REPICE, ANNA MARIA RITA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.719
EU - Europa 2.845
AS - Asia 850
AF - Africa 24
SA - Sud America 3
OC - Oceania 2
Totale 7.443
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.708
RU - Federazione Russa 1.187
PL - Polonia 559
IT - Italia 342
IE - Irlanda 328
CN - Cina 234
SE - Svezia 225
SG - Singapore 225
HK - Hong Kong 159
JO - Giordania 87
IN - India 73
DE - Germania 40
FI - Finlandia 34
GB - Regno Unito 30
CH - Svizzera 27
UA - Ucraina 26
CI - Costa d'Avorio 23
IR - Iran 22
SA - Arabia Saudita 21
ES - Italia 12
CA - Canada 11
FR - Francia 11
TR - Turchia 10
VN - Vietnam 10
BE - Belgio 8
KR - Corea 7
CZ - Repubblica Ceca 5
NL - Olanda 5
AT - Austria 3
LT - Lituania 3
AU - Australia 2
CL - Cile 2
IL - Israele 2
BR - Brasile 1
SC - Seychelles 1
Totale 7.443
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.404
Warsaw 558
Dublin 328
Chandler 284
Fairfield 275
Singapore 191
Ashburn 152
Hong Kong 112
Lawrence 106
Altamura 101
Woodbridge 101
Seattle 96
Beijing 90
Houston 85
Cambridge 76
Princeton 72
Wilmington 71
Florence 66
Ann Arbor 61
Milan 60
Mumbai 60
Buffalo 58
Boston 52
Kent 51
Shanghai 38
Dearborn 37
Moscow 37
Jacksonville 30
Bern 27
New York 27
San Diego 24
Abidjan 23
Medford 23
Riyadh 19
Los Angeles 17
Helsinki 16
Norwalk 15
Barcelona 12
Boardman 12
Rome 12
Falls Church 11
Yubileyny 11
London 10
Dong Ket 8
Guangzhou 8
Istanbul 8
Bremen 7
Frankfurt am Main 7
Lappeenranta 7
Seoul 7
Amman 6
Brussels 6
Hefei 6
Toronto 6
West Jordan 6
Brno 5
Nanjing 5
Tehran 5
Hillsboro 4
Kunming 4
Palermo 4
Phoenix 4
Pune 4
Redmond 4
Andover 3
Chennai 3
Falkenstein 3
Foggia 3
Fuzhou 3
Genoa 3
Hangzhou 3
Livorno 3
Ottawa 3
Redwood City 3
Romola 3
Vienna 3
Wuhan 3
Anderlecht 2
Auburn Hills 2
Aversa 2
Bologna 2
Buraidah 2
Campi Bisenzio 2
Chengdu 2
Chicago 2
Faenza 2
Forlì 2
Forney 2
Izmir 2
Jiaxing 2
Jinan 2
Kiryat Ono 2
Lyon 2
Notaresco 2
Pescara 2
San Giuliano Terme 2
Scandicci 2
Shenzhen 2
Sydney 2
Taranto 2
Totale 5.117
Salva come PNG Salva come JPEG
Nome #
Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy. 263
Azathioprine versus Beta Interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. 251
No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients. 244
Central vein sign differentiates MS from CNS inflammatory vasculopathies. 239
The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies 148
Safety and efficacy of autologous hematopoietic stem cell transplantation following natalizumab discontinuation in aggressive Multiple Sclerosis. 141
Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation 137
Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports. 136
Clinical characteristics predicting relapses following disease modifying therapies discontinuation in multiple sclerosis: a monocentric cohort study 120
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: The Italian multi-centre experience 120
Efficacy of Azathioprine on Multiple Sclerosis new brain lesions evaluated using Magnetic Resonance Imaging. 118
Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance 118
Modulating dendritic cells (DC) from immunogenic to tolerogenic responses: a novel mechanism of AZA/6-MP. 116
A whole genome screen for linkage disequilibrium in multiple sclerosis performed in a continental Italian population. 115
Severe disease reactivation in two multiple sclerosis patients after natalizumab withdrawal was not halted by monthly administrations of cyclophosphamide - two case reports 110
Effect of disease-modifying treatments on antibody-mediated response to anti- COVID19 vaccination in people with multiple sclerosis 110
The diagnosis of multiple sclerosis with markers of "better explanation": accuracy of the "central vein sign" in uncovering pathogenic mechansms different from inflammatory demyelination 108
CSF/serum matrix metallopeptidase‐9 ratio discriminates neuro Behçet from multiple sclerosis 108
MRI analysis of the "central vein sign" allows identification of a subset of relapsing remitting MS patients with brain pathology different from inflammatory demyelination 106
MRI evaluation of the "central vein sign" in brain white matter lesions of multiple sclerosis and systemic autoimmune diseases. 104
Association of celiac disease in patients with multiple sclerosis in Tuscany 102
Disappearance of motor tics after Wernicke's encephalopathy in a patient with Tourette's syndrome 99
Susceptibility weighted MRI can help differentiating pathogenesis of white matter lesions in MS and CNS inflammatory vasculopathies. 99
Accuracy of the central vein sign evaluation by brain MRI for the pathologic characterization of multiple sclerosis cases with markers of "better explanation" of the diagnosis. 99
Differentiation by MRI between multiple sclerosis and MS-like syndromes with markers of "better explanation" of the diagnosis. 95
Efficacy of autologous hematopoietic stem cell transplantation in secondary progressive Multiple sclerosis 94
CMV AND EBV REACTIVATION AFTER AUTOLOGOUS HAEMOPOIETIC STEM CELL TRANSPLANTATION WITH BEAM CONDITIONING REGIMEN FOR MULTIPLE SCLEROSIS AND LYMPHOMA: A RETROSPECTIVE SINGLE CENTER CASE-CONTROL STUDY 93
Mesenchymal Stem Cells and Autoimmune Diseases: The Case of Multiple Sclerosis 93
Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation 92
Prevalence of disability improvement as a potential outcome for multiple sclerosis trials 91
Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis. 91
Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis 89
Leptomeningeal enhancement analysis in diagnostic clinical setting 87
Neuropsychological assessment in aggressive multiple sclerosis treated with stem cell transplantation 86
Efficacy of Azathioprine on Multiple Sclerosis new brain lesions evaluated by Magnetic Resonance Imaging. 86
HSCT for severe multiple sclerosis with BEAM/ATG: impact on female fertility 86
A case of recurrent progressive multifocal leukoencephalopathy after human stem cell transplant, with detection of John Cunningham virus and human herpesvirus 6 on cerebrospinal fluid, treated with Mirtazapine, Olanzapine and Foscarnet 85
Cerebral perfusion abnormalities in multiple sclerosis patients with markers of systemic autoimmunity 84
Management of viral reactivation in multiple sclerosis patients after autologous transplantation with BEAM/ATG conditioning regimen 84
Comparative long term efficacy of beta interferons and azathioprine in relapsing-remitting Multiple sclerosis: single center retrospective 25 year evaluation 83
Direct comparison of Azathioprine and Interferon beta 1a efficacy on prevention of new brain lesions in relapsing-remitting multiple sclerosis 82
The Central Vein Sign identifies patients diagnosed with multiple sclerosis probably carrying different diseases and showing milder disease course 82
CMV and EBV reactivation in autologous haemopoietic stem cell transplantation for severe multiple sclerosis 81
Imaging perivenular distribution can differentiate MS from CNS vasculitis. 80
Evaluation of dimethyl fumarate efficacy and safety in patients with relapsing remitting multiple sclerosis switching from other treatments 80
Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience 80
Reconstitution of natural or vaccination-driven immunity after aHSCT in multiple sclerosis 79
Brain atrophy evaluation in multiple sclerosis: change over time of corpus callosum area is more sensitive and reproducible than whole brain volume 79
Long term follow-up of autologous stem cell transplantation (HSCT) for the treatment of secondary progressive multiple sclerosis: single centre experience 79
Safety profile of autologous haematopoietic stem cell transplantation following natalizumab therapy in aggressive forms of multiple sclerosis 78
Comparison of azathioprine and of beta interferon efficacy on measures of brain damage evaluated by MRI in relapsing-remitting multiple sclerosis 78
Soluble factor profile in Natalizumab treated MS patients: increased Th1 promoting factors and sHLAg 77
Impact of new DMAs on the safety profile of patients undergoing autologous haematopoietic stem cell transplantation for Multiple Sclerosis 76
intermediate intensity regimen in autologous HSCT for severe Multiple Sclerosis: a a large, single center experience 76
Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: a population-based study on Tuscan residents 76
MS patients with low central vein sign frequency can be identified by FLAIR* MRi sequences 75
Real Life comparative evaluation of dimethyl fumarate efficacy and tolerability in relapsing remitting multiple sclerosis patients switching from other treatments 75
Azathioprine-interferon beta 1a s.c. association in relapsing-remitting multiple sclerosis: compliance and efficacy in prevention of new brain lesions 75
Autologous hematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis 75
Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis. 74
Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience 73
Clinical and paraclinical findings in a case series of MOGAD: Exploring the presence of perivenular brain white matter lesions 73
CNS inflammation during relapsing remitting multiple sclerosis (RRMS): a molecular and cellular analysis of ex vivo CSF T lymphocyte expansions 73
Azathioprine versus interferon-beta-1a s.c.: efficacy on prevention of new brain lesions in relapsing-remitting multiple sclerosis 73
MMP9 index as possible diagnostic marker of Neuro-Behcet's disease 72
Absence of association between intronic polymorphism in PS-1 gene and alzheimer's disease in italian patients 71
Purely myeloablative conditioning regimen in aggressive multiple sclerosis: two case reports 71
Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis 71
Intermediate intensity regimen in autologous HSCT for severe multiple sclerosis: a large, single center experience 69
Azathioprine and interferon beta1a relative efficacy on prevention of new brain lesions in relapsing remitting multiple sclerosis 67
Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis 65
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis 65
Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation 64
Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis 63
Antigen Driven T-Cell Response in CSF of Multiple Sclerosis Patients 63
Case report: A multiple sclerosis patient with imaging features of glymphatic failure benefitted from CSF flow shunting 59
Identification of single nucleotide variations in the coding and regulatory regions of the myelin-associated glycoprotein gene (MAG) and study of their association with multiple sclerosis. 59
Cyclophosphamide pulses therapy after natalizumab discontinuation in Multiple Sclerosis patients 58
Impact of autologous haematopoietic stem cell transplantation on fertility in aggressive multiple sclerosis 53
Thymic hyperplasia after autologous hematopoietic stem cell transplantation in multiple sclerosis: a case series 21
Totale 7.570
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.818
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.818
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020474 0 0 0 0 0 67 87 79 61 84 82 14
2020/2021466 40 41 16 62 59 50 26 36 37 59 16 24
2021/2022444 7 46 23 33 14 13 13 47 22 15 72 139
2022/20231.424 104 268 99 53 95 247 193 83 194 3 47 38
2023/2024750 23 94 84 53 67 82 36 135 18 42 74 42
2024/20253.270 190 435 276 689 1.075 605 0 0 0 0 0 0
Totale 7.570